Arena and Eisai are testing Belviq with appetite suppressant phentermine.
A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
The drugmaker's new subsidiary will provide behavior and activity training, among other services.
The company expects to join the prescription weight-loss market by 2014's third quarter.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
Researchers think a two-hormone approach could help control diabetes and obesity.
The marketing push follows the September launch of a patient support program and the announcement it was doubling its sales force.
Eisai, the marketing half of the Arena-Eisai collaboration, plans to double the sales force by December.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec's appointment.
The Centers for Disease Control and Prevention profiles the typical sleep aid user, and finds that eight hours does not mean consumers are sleeping without help.
Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration
Eisai uses a lawsuit to prompt the DEA, AHRQ gets a new director, mWellness runs into adherence issues.
Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back
GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues
Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.
Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.
Alexion plans on moving into new HQ in 2015, AMA declares obesity is a disease, FDA looks into Zyprexa patient deaths
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.
AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight loss results.
Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.
HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
Arena gets closer to the market place, Takeda scoops up privately held Inviragen, Plan B court decision is coming and Cubist antibotic lands breakthrough therapy status.
Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.
When it comes to OTC weight-loss products, deceptive advertising produces diminishing returns, a study has found.
Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.